CRCM
BSX icon

Crystal Rock Capital Management’s Boston Scientific BSX Stock Holding History

Crystal Rock Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.18M Sell
50,645
-8,375
-14% -$670K 1.89% 22
2025
Q4 		$5.63M Hold
59,020
– – 2.97% 14
2025
Q3 		$5.76M Sell
59,020
-5,750
-9% -$595K 3.15% 13
2025
Q2 		$6.96M Sell
64,770
-4,550
-7% -$460K 4.01% 9
2025
Q1 		$6.99M Sell
69,320
-15,780
-19% -$1.59M 4.78% 7
2024
Q4 		$7.6M Sell
85,100
-6,425
-7% -$566K 4.66% 8
2024
Q3 		$7.67M Sell
91,525
-3,350
-4% -$264K 4.52% 8
2024
Q2 		$7.31M Hold
94,875
– – 4.37% 8
2024
Q1 		$6.5M Hold
94,875
– – 3.78% 9
2023
Q4 		$5.48M Sell
94,875
-4,500
-5% -$240K 3.62% 10
2023
Q3 		$5.25M Hold
99,375
– – 4% 8
2023
Q2 		$5.38M Hold
99,375
– – 3.98% 9
2023
Q1 		$4.97M Sell
99,375
-18,000
-15% -$848K 4.12% 11
2022
Q4 		$5.43M Hold
117,375
– – 4.68% 7
2022
Q3 		$4.55M Buy
117,375
+8,800
+8% +$353K 4.68% 7
2022
Q2 		$4.05M Buy
108,575
+6,000
+6% +$244K 3.84% 13
2022
Q1 		$4.54M Hold
102,575
– – 3.01% 16
2021
Q4 		$4.36M Hold
102,575
– – 2.35% 18
2021
Q3 		$4.45M Buy
102,575
+3,600
+4% +$159K 2.37% 19
2021
Q2 		$4.23M Hold
98,975
– – 2.2% 19
2021
Q1 		$3.83M Sell
98,975
-8,200
-8% -$310K 2.08% 20
2020
Q4 		$3.85M Sell
107,175
-8,300
-7% -$299K 2.2% 20
2020
Q3 		$4.41M Hold
115,475
– – 2.78% 11
2020
Q2 		$4.05M Buy
115,475
+8,400
+8% +$303K 2.8% 14
2020
Q1 		$3.49M Buy
107,075
+77,075
+257% +$3.01M 3.08% 15
2019
Q4 		$1.36M Buy
+30,000
New +$1.26M 0.89% 29

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Crystal Rock Capital Management's BSX Position: Q1 2026 in Review

Crystal Rock Capital Management reduced its Boston Scientific (BSX) stake by 14% in Q1 2026, selling an estimated $670K and leaving 50,645 shares worth $3.18M. The position accounts for 1.89% of the portfolio, ranked #22.

Crystal Rock Capital Management first reported a position in BSX in Q4 2019 and has held it in 26 quarters since. The position peaked at $7.67M in Q3 2024. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Crystal Rock Capital Management held 50,645 shares of Boston Scientific worth $3.18M as of Q1 2026.
  • Crystal Rock Capital Management sold 8,375 Boston Scientific shares in Q1 2026, an estimated $670K.
  • Boston Scientific made up 1.89% of Crystal Rock Capital Management's portfolio in Q1 2026, its #22 holding.
  • Crystal Rock Capital Management first reported a position in Boston Scientific in Q4 2019 and has held it in 26 quarters since.
  • Crystal Rock Capital Management's Boston Scientific position peaked at $7.67M in Q3 2024.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Crystal Rock Capital Management's 13F filing for Q1 2026, filed 4 May 2026.